News

2017

Ovid Therapeutics

August 10, 2017 - Ovid Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Progress

View PDF 

 

Evidation Health

July 31, 2017 - Sanofi Strengthens Ties with Evidation Health, Leader in Quantifying Health Behaviors

View PDF 

 

NeuroVia

July 20, 2017 - NeuroVia Closes Series A Financing Round of $14M to Develop Novel Treatment Option for X-ALD Disease

View PDF 

 

Ovid Therapeutics

June 23, 2017 - Ovid Therapeutics to be Added to Russell 2000®, 3000® and Microcap® Indexes

View PDF 

 

Omada Health

June 14, 2017 - Omada Health Raises $50 Million, Led by Cigna

View PDF 

 

Ovid Therapeutics

June 13, 2017 - Ovid Therapeutics Reports First Quarter 2017 Financial Results and Recent Corporate Progress

View PDF 

 

Immune Design

May 17, 2017 - Immune Design Reports First Quarter 2017 Financial Results and Provides Corporate Update

View PDF 

 

Immune Design

May 17, 2017 - New Clinical and Biomarker Data Validate Immune Design's Lead Programs and Discovery Platforms

View PDF 

 

Evidation Health

April 27, 2017 - Evidation Health secures Financing from Sanofi-Genzyme BioVentures to Fuel Commercial Growth

View PDF 

 

Science 37

April 25, 2017 - Science 37 Raises $29M To Bring Clinical Trials Directly Into Patients' Homes

View PDF

 

Ovid Therapeutics

April 10, 2017 - Ovid Therapeutics Announces Initiation of Phase 1 Clinical Trial of OV101 for Adolescents with Angelman Syndrome or Fragile X Syndrome

View PDF

 

GlycoMimetrics

March 7, 2017 - GlycoMimetrics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271

View PDF

 

Science 37

March 1, 2017 - Science 37 and Sanofi Introduce a New Partnership

View PDF

 

Immune Design

March 7, 2017 - Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update.

View PDF

 

Immune Design

March 1, 2017 - Immune Design To Present New Tumor Eradication Data for Systemic Plus Intratumoral Immunization at AACR Annual Meeting 2017.

View PDF

 

Immune Design

February 22, 2017 - Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate

View PDF

 

Ovid Therapeutics

February 9, 2017 - Ovid Therapeutics Announces First Patient Randomized in the Phase 2 STARS Clinical Trial in Adults with Angelman Syndrome

View PDF

 

Ovid Therapeutics

February 9, 2017 - Ovid Therapeutics and NeuroPointDX Announce Collaboration to Identify Biomarkers for Angelman

View PDF

 

Ovid Therapeutics

January 19, 2017 - Ovid Therapeutics Names Jacqueline A. French, M.D. to Scientific Advisory Board

View PDF

 

Ovid Therapeutics

January 18, 2017 - Takeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in Rare Pediatric Epilepsies

View PDF

 

Lysosomal Therapeutics

January 9, 2017 - Allergan Enters Parkinson's Disease Through Option Arrangement with Lysosomal Therapeutics Inc. (LTI) for its Potential First-in-Class Breakthrough Compounds

View PDF

 

Immune Design

December 5, 2016 - Immune Design Provides Update from Two Discovery Platforms:  DC-tropic ZVex and G100

View PDF

 

Immune Design

November 11, 2016 - Immune Design Reports Third Quarter 2016 Financial Results and Provides Corporate Update

View PDF

 

Science 37

October 18, 2016 - Science 37 Secures $31M Series B Funding to Expand Clinical Trial Access to Anyone, Anywhere, Anytime

View PDF

 

Immune Design

September 28, 2016 -Immune Design Announces Advancement of First GLAAS™-based Allergy Program into Clinical Development

  View PDF

 

Ovid Therapeutics

September 8, 2016 - Ovid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for the Treatment of Patients with Angelman Syndrome

  View PDF

 

Yumanity Therapeutics

June 22, 2016 - Yumanity Therapeutics and the New York Stem Cell Foundation Research Institute Announce Discovery Collaboration

   View PDF

 

Immune Design

June 8, 2016 - Immune Design Releases New PFS, OS and TME Data from Trials of Three Immuno-Oncology Product Candidates

 View PDF

 

Immune Design

May 10, 2016 - Immune Design Reports First Quarter 2016 Financial Results and Provides Corporate Update

 View PDF

 

Immune Design

May 9, 2016 - Immune Design and Gritstone Oncology Announce Clinical Collaboration for Neoantigen Cancer Immunotherapy.

 View PDF

 

Immune Design

April 20, 2016 - Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches

 View PDF

 

ImmuneXcite

March 30, 2016 - ImmuneXcite Closes $8.6M Financing, Adds Three Industry Veterans to Company Leadership

 View PDF

 

Immune Design

March 10, 2016 - Immune Design Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update

 View PDF

 

Immune Design

March 4, 2016 - Immune Design's GLAAS™ Platform Shown to Modulate the Allergic Immune Response

 View PDF

 

Proteostasis Therapeutics

February 11, 2016 - Proteostasis Therapeutics, Inc. Announces Pricing of Initial Public Offering

View PDF

 

Yumanity Therapeutics

February 10, 2016 - Yumanity Therapeutics Closes $45 Million Series A Financing

View PDF

 

Immune Design

February 9, 2016 - Immune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-oncology Product Candidates

View PDF

 

Proteostasis Therapeutics

February 1, 2016 - Proteostasis Therapeutics Receives FDA Fast Track Designation for PTI-428 in Patients with Cystic Fibrosis

View PDF

 

Unum Therapeutics

January 26, 2016 - Unum Therapeutics Moves to New Headquarters in Cambridge, MA as it continues to Expand and Advance its Cellular Immunotherapy Pipeline

View PDF

 

Immune Design

January 8, 2016 - Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305

View PDF